abstract
T he association between corticosteroid administration and osteonecrosis is well known.
1, 2 The majority of reports on steroid-induced osteonecrosis involve long-term, highdose steroid administration and chronic disease. Many musculoskeletal physicians routinely use short-term, low-dose corticosteroids to treat acute inflammation, 3 such as a 21-tablet, 4-mg methylprednisolone taper pack (MTP) taken over a 6-day period. However, the risk of osteonecrosis following these commonly used steroid taper packs is not well known.
Because osteonecrosis is such a rare complication after low-dose corticosteroid administration, its incidence is difficult to accurately estimate unless patient data across large populations are accessible. As the US federal government mandates that health care providers transition to electronic medical records for documentation, more pooled health care data are becoming accessible. Although this process can be cumbersome and costly for many hospitals and physicians, a potential benefit of this digital transition is that more patient data across large populations in the United States will be available for analysis. New software platforms are becoming available that allow an investigator to search massive amounts of pooled health care data for quality improvement and research purposes. 4, 5 The goal of the current study was to report the incidence and risk of osteonecrosis after an MTP prescription using a novel software platform to query a multicenter electronic medical database. The hypothesis was that short-term, low-dose oral corticosteroid administration results in a low but increased rate of osteonecrosis.
Materials and Methods
A large, multicenter database of 14 major health care systems in the United States was used to investigate the incidence of osteonecrosis in patients who had received an MTP. A commercially available software platform (Explorys; Explorys, Inc, Cleveland, Ohio) was used to query the database. This software enables the user to efficiently analyze key components of the medical records of a large population of patients to determine associations. Because only de-identified data were accessed, this study was deemed exempt from the author's institutional review board. To ensure Health Insurance Portability and Accountability Act (HIPAA) compliance for small patient groups with rare diseases, the Explorys platform rounds patient numbers to the nearest 10 so that they could not be readily re-identified.
Patient cohorts were created using Explorys software to query the database on May 15, 2013, to identify patient who had been prescribed an MTP. The common MTP used was a 21-tablet packet of 4-mg methylprednisolone administered in a tapered fashion over a 6-day period. The generic version of the medication was queried, which includes both the generic and proprietary medication (4-mg Medrol Dosepak; Pfizer, New York, New York). Group 1 comprised all patients who had ever been prescribed an MTP, group 2 comprised all patients who had only been prescribed a single MTP over their documented clinical history, group 3 comprised all patients who had been prescribed 2 or more MTPs, and the control group comprised all patients who had never been prescribed an MTP. Groups were further categorized according to sex ( Table 1 ).
All patients who had been prescribed any type of glucocorticoid prior to the prescription of MTP were excluded from all groups. This was done in an attempt to isolate the effect of a single MTP, which would exclude patients on chronic steroid administration who often have multiple medical issues and chronic diseases that put them at risk for osteonecrosis. In addition, all patients who were diagnosed with any type of osteonecrosis prior to the index event of an MTP prescription were excluded from the study. bone, other). The incidence of osteonecrosis was then calculated in each group using the ICD-9 codes listed above. Each group was then subclassified according to sex and ICD-9 osteonecrosis location.
The incidence of osteonecrosis within the manufactured cohorts was determined, and the relative risk was then calculated for this cohort study. Pearson's chi-square statistical instrument for comparing proportions of categorical variables was used to determine significance with a P value of .05. Ninety-five percent confidence intervals (CIs) were determined for all calculations.
results
A total of 24,533,880 patient medical records were available in the database at the time of the query. A total of 98,390 patients were identified who had been prescribed only a single MTP at some time during their electronic medical existence within the system after excluding patients who had received any glucocorticoid product or had a preexisting diagnosis of osteonecrosis prior to the prescription of an MTP. Of this group, 130 (0.132%; 95% CI, 0.109%-0.155%) were subsequently diagnosed with osteonecrosis after that single prescription ( Table 2) . This resulted in a relative risk of 1.597 (95% CI, 1.339-1.843) when compared with the control population, with a statistically significant difference between groups (P<.001) ( Table 3) . Similarly, a statistically significant difference in the incidence of osteonecrosis was also found between patients who had received 2 or more MTPs (0.230%; 95% CI, 0.176%-0.283%) and the control group (relative risk, 2.763; 95% CI, 2.186-3.341).
Statistical significance was also observed between the control group and all patients who had received one or more MTPs regardless of sex, with the exception of 30 of 47,530 males who had received a single MTP with the specific diagnosis of osteonecrosis of the femoral head (0.063%; 95% CI, 0.041%-0.086%; P=.213). However, significantly more male patients were diagnosed with osteonecrosis of a nonspecific location after a single MTP (60 of 47,530; 0.126%; 95% CI, 0.094%-0.158%) than the male control group (P=.004). Females who had been prescribed more than one MTP without prior steroid prescriptions or osteonecrosis diagnoses had the highest incidence of osteonecrosis (0.247%; 95% CI, 0.171%-0.324%), with a relative risk of 3.094 when compared with the sexmatched control (P<.001).
Data were analyzed to determine the incidence of osteonecrosis specific to location as defined by ICD-9 code (head of femur, head of humerus, talus, and medial femoral condyle). However, fewer than 10 patients were found in most groups for the humerus, talus, and medial femoral condyle codes, which prohibited statistical analysis. One of the limitations of the Exlorys system is that it will not allow the user to identify cohorts of fewer than 10 patients within the global multicenter database to ensure HIPAA compliance.
discussion
This study demonstrates that even a single prescription of short-term, lowdose oral corticosteroid administration is associated with a low but significantly increased risk of being diagnosed with osteonecrosis. In patients who had received multiple MTP prescriptions, the risk is even greater when compared with the control population. Prior to this study, this association was presumed but never quantified. In a survey of 1290 sports medicine physicians, 8.5% of those surveyed reported that they had seen a patient diagnosed with osteonecrosis as a complication of MTP use. 3 Although there had been little evidence linking single MTP use and osteonecrosis, the most common reason that the physicians surveyed did not routinely prescribed MTPs was fear of osteonecrosis. The current study is the first to quantify this association and can be used to counsel patients about the risks and benefits of short-term corticosteroid use.
Osteonecrosis has been described as vascular compromise from various etiologies leading to in situ death of cells within bone. Although osteonecrosis is the preferred term, the process has also been described as avascular necrosis, aseptic necrosis, bone necrosis, ischemic necrosis, or bone infarcts. 6 The rate of osteonecrosis in the general population has been estimated to be between 0.0014% and 0.003%, with the hip being the most common area affected. 7, 8 Osteonecrosis has been estimated to be responsible for more than 10% of total hip arthroplasties performed in the United States and Western Europe. 6, 9 The association between corticosteroid administration and osteonecrosis has been well documented, 1,2,8,10 but most cases of osteonecrosis involve long-term, high-dose steroid administration and n Feature Article Multiple cases of the development of osteonecrosis after short-term, low-dose oral steroid administration have been described, but the majority of these reports consist of individual patients within a large cohort, small cases series, or case reports. [10] [11] [12] [13] [14] In 1982, Anderton and Helm 11 published one of the first reports of the development of proximal humeral osteonecrosis after short-term, low-dose oral steroid administration for intracranial hypertension in an otherwise healthy 23-year-old man. Wong et al 15 reported a 0.3% (4 of 1352) prevalence of neurosurgical patients who developed osteonecrosis after a short-term, highdose corticosteroid treatment resulting in osteonecrosis of the femoral head. This population differs from the cohort described in the current study because the patients in the study by Wong et al 15 had received high-dose corticosteroids.
Corticosteroids are commonly prescribed to treat many dermatological, respiratory, gastrointestinal, neurologic, and musculoskeletal inflammatory conditions. As a result, corticosteroid use is the most commonly described nontraumatic risk factor for the development of osteonecrosis. 7, 16 The widespread use of MTPs for these common conditions in often otherwise healthy patients and the potentially devastating sequelae of osteonecrosis after their use can be a source of significant contention and litigation between the patient and prescribing physician. 17, 18 The recommendation for physicians who prescribe MTPs universally involves shared deci- Table 2 Incidence of Osteonecrosis sion making, informed consent, and thorough documentation. The low incidence of osteonecrosis (0.132%) in patients after a single MTP found in the current study may contribute to a more educated doctorpatient conversation regarding the rare but real risk of a potentially devastating complication after short-term, low-dose corticosteroid administration.
As all US health care systems are mandated to adopt electronic medical records, more patient data will be available for analysis across large populations. These large databases of medical information will become a useful resource to investigate rare diseases and complications in a way that was improbable prior to the digitalization of medicine. 4, 5 Using pooled electronic medical data for research is not without limitations. Medication prescriptions are recorded in the medical record, and it cannot be confirmed that the patient was compliant in taking the medication. The integrity of the database is completely dependent on accurate data entry by the health care administrator. Bozic et al 19 recently reported on the accuracy of an administratively coded medical database and concluded that comorbidities and complications coded in the administrative record were accurate but often incomplete.
When extrapolating the results of the study by Bozic et al 19 to the current study, one would conclude that the 0.19% incidence of osteonecrosis following a single MTP is possibly an underestimation due to undercoding or miscoding.
Another limitation to this specific database is that the Explorys platform rounds patient numbers to the nearest 10 so that they can not be readily reidentified to maintain HIPAA compliance, and this limits the precision of the results obtained in this study. Patients may be lost to follow-up due to changing to a different health care system that does not contribute its health information to the database. Finally, osteonecrosis has multiple etiologies, so only an association, not causation, can be inferred from a large database analysis such as the current study. Common causes of osteonecrosis, such as alcohol, radiation therapy, chemotherapy, organ transplantation, systemic lupus erythematosus, sickle cell disease, HIV, or Gaucher's disease, may have been the etiology of osteonecrosis in any patient in this study.
conclusion
Short-term, low-dose oral corticosteroid administration is associated with a low but statistically significant increased incidence of osteonecrosis compared with patients who have never been prescribed a steroid product. To the author's knowledge, this is the first study in the literature to estimate the incidence of osteonecrosis after shortterm, low-dose oral corticosteroid administration across a large population: 0.132% of patients were subsequently diagnosed with osteonecrosis after a single MTP had been prescribed, with a relative risk of 1.591 when compared with the control population. These data can be used when counseling patients about the risks vs benefits of short-term corticosteroid use. As more physicians and health care systems are mandated to adopt electronic medical records by the United States government, more patient data will be available for analysis across large populations. These pooled electronic medical data are a useful resource for investigating rare pathology, such as the association between osteonecrosis after short-term, low-dose oral corticosteroid administration. n Feature Article 
